Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The case for GLP-1 drugs as cancer fighters keeps getting stronger. More than a dozen studies at ASCO 2026 linked these popular diabetes and weight-loss medications to lower risks of breast cancer, leukemia, lung cancer, liver cancer, and reduced metastatic progression across multiple tumor types. Experts say the signal is compelling enough to launch a prospective clinical trial — but stress that retrospective data alone can't prove causation.
The evidence connecting GLP-1 receptor agonists to cancer protection has reached a new inflection point. More than a dozen studies presented at the 2026 ASCO Annual Meeting linked these widely used diabetes and obesity medications to lower risks of breast cancer, leukemia, lung cancer, and hepatocellular carcinoma — and to reduced progression to metastatic disease across multiple solid tumor types. Notably, some benefits appeared in cancers not classically tied to obesity, hinting at mechanisms beyond weight loss, such as reduced inflammation and direct anti-tumor effects.
Researchers are now moving toward prospective validation. A multisite international trial called INSPIRE is being finalized to test GLP-1s in breast cancer prevention among high-risk women, drawing from a pool of 108,000+ participants in an existing mammography trial. Meanwhile, experts caution that all current findings come from retrospective database studies — which are prone to bias and cannot establish causality — and point to metformin as a cautionary tale where retrospective promise didn't hold up in trials.
By the Numbers
Why it matters: If prospective trials confirm even a fraction of these associations, GLP-1s could become the first broadly accessible pharmacologic tool for cancer prevention — potentially sparing thousands of patients from ever developing the disease.
